2,098
Participants
Start Date
October 31, 2007
Primary Completion Date
June 30, 2008
Study Completion Date
November 30, 2008
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)
0.1 mL, Intradermal (ID)
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)
0.1 mL, Intradermal (ID)
Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
0.5 mL, Intramuscular (IM)
Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
0.5 mL, Intramuscular (IM)
Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
0.5 mL, Intramuscular (IM)
Alabaster
Mobile
Chandler
Mesa
Phoenix
Tucson
Fountain Valley
San Diego
Stanford
Pembroke Pines
Pinellas Park
Boise
Chicago
Wichita
Kansas City
Springfield
St Louis
Cary
Raleigh
Cincinnati
Allentown
Bensalem
Warwick
Goose Creek
Fort Worth
Galveston
Salt Lake City
West Jordan
Marshfield
Lead Sponsor
Sanofi
INDUSTRY